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Background: Obesity is a global epidemic that is impacting children around the world. Obesity is a chronic
inflammatory state with enhanced production of multiple cytokines and chemokines. Chemokine (C-C motif) Ligand
2 (CCL2) is produced by immune and metabolic cells and attracts immune cells into liver, muscle and adipose
tissue, resulting in initiation and propagation of the inflammatory response in obesity. How obesity and fitness
affect the production of this chemokine in children is unknown.
This study tested the hypotheses that CCL2 levels are higher in obese children when compared to lean controls,
and that fitness modulates CCL2 levels allowing its use as a biomarker of fitness.
Methods: This was a cross sectional case–control study conducted in a Pediatric Tertiary care center in Hamilton,
Ontario, Canada. Controls were recruited from the community. This study recruited overweight/obese children
(BMI ≥ 85th percentile, n = 18, 9 female, mean age 14.0 ± 2.6 years) and lean controls (BMI < 85th percentile, n = 18,
8 female, mean age 14.0 ± 2.6 years) matched for age, sex and biological maturation.
Aerobic fitness test was done using a cycle ergometer performing the McMaster All-Out Progressive Continuous
Cycling test to exhaustion to determine peak oxygen uptake. Fasting CCL2 samples were taken prior to test.
Categorical variables including subject categorization into different aerobic fitness levels in overweight/obese and
lean children was reported based on the median split in each group.
Results: Obese participants had significantly higher CCL2 levels when compared to lean group
(150.4 ± 61.85 pg/ml versus 112.7 ± 38 pg/ml, p-value 0.034).
To establish if CCL2 is a biomarker of fitness, we divided the groups based on their fitness levels. There was a main
effect for group (F (3,32) = 3.2, p = 0.036). Obese high fitness group were similar to lean unfit and fit participants.
Post-hoc analysis revealed that the overweight/obese low fitness group had significantly higher level of CCL2
compared to the lean low fitness group when adjusted to age, sex and maturity offset (F (3,29) = 3.1, p = 0.04).
Conclusions: CCL2 serves a dual role as a potential biomarker of inflammation and fitness in obese children.
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Obesity is a protective evolutionary mechanism that helped
humankind survive famine and, as such, is as old as hu-
manity. This once adaptive mechanism has become coun-
terproductive in modern society, due to unprecedented
lifestyle changes that have resulted in an obesity epidemic
on a global scale, with 1.5 billion adults and 200 million
children and adolescents being overweight or obese [1-4].
Some of the obesogenic factors in the environment in-
clude the constant availability and affordability of food in
general, and especially processed foods and sugary drinks
[5-7]. In addition, the reduction in physical activity at home
and in school [8], the reliance on the use of technology,
and shorter duration of sleep [9] are some of the precursors
involved in the genesis of childhood obesity. These ele-
ments interact with each other and with genetic and epi-
genetic factors to mediate the body’s response to excess
weight, and this is an area of intensive research. However,
the mechanisms that lead to the initiation of obesity are not
yet identified, and understanding the mechanisms that start
and propagate obesity will help define interventions for its
treatment and prevention.
The significance of childhood obesity lies in its as-
sociation with other comorbidities in children includ-
ing glucose intolerance, type 2 diabetes, dyslipidemia,
hypertension, obstructive sleep apnea, gastroesopha-
geal reflux, and joint problems [10]. In addition, many
obese children are likely to become obese adults, with
increased risk of adverse health outcomes including
cardiovascular disease and diabetes [10,11].
Pediatric weight management programs focus on life
style interventions to manage obesity, and one pillar of
these programs is exercise [12]. An important aspect of
designing exercise regimens involves the determination
of fitness levels to aid with the provision of a targeted
exercise plan. Fitness testing requires the existence of
a significant infrastructure of equipment and trained
personnel, adding to the complexity and cost of care
provided. To date, there has been no fitness biomarkers
identified that allows us to allocate children to specific
exercise programs without the need for costly exercise
testing.
On a mechanistic level, obesity is associated with a
chronic low-grade inflammatory state [13], characterized
by activation of the innate immune system and infiltra-
tion of immune cells into metabolic organs including
adipose tissue, skeletal muscle and liver [14,15].
The signals that attract immune cells into these organs
include a set of cytokines, called chemokines, that have
the ability to regulate leukocyte traffic into tissues [16].
One such chemokine is Chemokine (C-C motif )
Ligand 2 (CCL2), also known as Monocyte Chemo-
attractant Protein-1 (MCP-1). The adipocyte is a major
source of CCL2 in obesity, the production of which istriggered when cells are exposed to inflammatory cyto-
kines and fatty acids [17], and recently, microRNAs 126
and 193b have also been implicated in the regulation of
CCL2 secretion in obese adipose tissue [18]. Other cells
are capable of secreting CCL2 in obesity including hepato-
cytes [19], skeletal muscle cells [15], monocytes, vascular
smooth muscle and endothelial cells [20].
The role of CCL2 in childhood obesity is not well
studied. Circulating CCL2 levels are increased in obese
adults and children [21,22], and correlate positively with
BMI and other inflammatory markers like C-Reactive
Protein and Interleukin-6 and negatively with High Den-
sity lipoprotein (HDL) [23]. CCL2 administration causes
insulin resistance in mice [24], although there is con-
flicting evidence to its correlation with insulin resistance
in adult humans [23,25,26].
In addition, CCL2 has also been implicated in mono-
cyte infiltration into atherosclerotic plaques and exacer-
bation of atherosclerosis [27]. Weight loss and exercise
lead to a reduction in CCL2 levels, and improved insulin
sensitivity [22,28].
While CCL2 has been implicated in inflammation and
insulin resistance, its correlation with fitness has not
been studied previously. As CCL2 levels are elevated
in obesity and is associated with inflammation and in-
sulin resistance, and as exercise lowers CCL2 levels,
the aim of this study was to test the hypothesis that
CCL2 levels are higher in obese children when com-
pared to lean controls, and that CCL2 levels are higher in
children with low fitness levels when compared to fit chil-
dren reflecting a more robust inflammatory response. We
predicted that this molecule could serve a dual role as a
biomarker of fitness and inflammation in children.
Methods
Study design and protocol
This was a cross sectional case – control study conduc-
ted at a tertiary pediatric center in Hamilton, Ontario,
Canada. The Hamilton Health Sciences/Faculty of Health
Sciences Research Ethics Board approved the study proto-
col, and the study was conducted in compliance with the
declaration of Helsinki for protection of human research
subjects. The primary outcome of the study is CCL2 dif-
ferences between lean and overweight/obese participants,
and the secondary outcome is the detection of differences
between lean and overweight/obese groups based on fit-
ness levels.
Study participants
A total of 18 overweight or obese children (7 with BMI
between 85th–95th percentile, 11 with BMI ≥95th per-
centile, 9 female, mean age 14.0 ± 2.60 years) and 18 lean
controls (BMI < 85th percentile, 8 female, mean age 14.0 ±
2.60 years) were matched for chronological age, sex and
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from the age of peak height velocity [29]. Overweight and
obese children were recruited from the weight mana-
gement program at the Children’s Exercise & Nutrition
Centre and lean controls were recruited from the local
community through advertisements distributed through
schools. Participant characteristics are shown in Table 1.
Protocol
Upon full explanation of the study protocol, participants
signed an assent form and parents/guardians signed the
consent form.
Participants’ height (Harpenden Stadiometer) and
weight (BWB-800, Tanita Corporation, Japan) were then
measured, along with body composition as assessed by
dual energy x-ray absorptiometry (DEXA), and lung func-
tion using standard spirometry tests. An aerobic fitness
test performed on a cycle ergometer was then used to
determine peak oxygen uptake as per the previously de-
scribed McMaster All-Out Progressive Continuous Cyc-
ling test [30]. Progression in this test is achieved by an
increase in resistance every 2 min. The test is constructed
according to body height such that the total exercise time
will range from 8 to 12 min for most children. In adults, it
is common to assign specific criteria to determine whether




obese (N = 18)
P-value
Sex F:M 8:10 9:9 1.00
Age (years) Mean 14.00 14.00 0.99
SD 2.60 2.60
YPHV (years) Mean 1.10 1.50 0.47
SD 2.10 2.10
Height (m) Mean 1.65 1.66 0.99
SD 0.16 0.16
Weight (kg) Mean 52.60 82.40 <0.001
SD 12.90 28.80
BMI (kg/m2) Mean 19.00 29.3 <0.001
SD 2.20 6.80
BMI percentile Mean 46.20 95.00 <0.001
SD 26.30 4.90
%FM DEXA Mean 18.00 33.80 <0.001
SD 6.60 9.20




Mean 66.40 58.60 0.016
SD 8.60 9.80
YPHV = years from peak height velocity; BMI = body mass index;%FM DEXA =
percentage of fat mass using dual x-ray absorptiometry; VO2max =maximal
oxygen consumption; VO2max-Lean =maximal oxygen consumption adjusted
to lean body mass; SD = standard deviation. Independent sample t-test was
used for analysis.criteria have little value; for example, a plateau in VO2
with increasing power output occurs in only about 50% of
children, and equations of age-predicted maximum heart
rate are not accurate during childhood because maximal
heart rate remains constant during growth. Therefore,
the pediatric-specific criteria we used included: a heart
rate of ≥195 beats per minute, a respiratory exchange
ratio (RER) ≥ 1.0, and an inability to maintain the pre-
scribed pedaling cadence in spite of strong verbal
encouragement.
In our experience, a motivated child who is attempting
to maintain the appropriate cadence, but cannot do so,
in spite of encouragement is very likely to have reached
their limit. Measurements of expired O2 and CO2 were
made continuously using a calibrated metabolic cart
(VMAX 29, SensorMedics, Yorba Linda, CA, U.S.A.),
with appropriately sized pediatric mouthpieces.Blood sampling & analysis
Serum samples were collected following a 10-hour over-
night fast. Fasting lipids (triglycerides, cholesterol, LDL,
and HDL) were analyzed at the McMaster University
Medical Center core laboratory using Roche P Module
and standard Roche reagents. Serum samples were ana-
lyzed for fasting glucose using an assay kit (Cayman
Chemical Company, Ann Arbor, Michigan), fasting insulin
using an ELISA kit (Invitrogen Corporation, Carlsbad,
California), and CCL2 using R&D systems CCL2/MCP-1
Quantikine human ELISA kit (Cedarlane, Oakville,
Ontario). The intra-assay variation coefficients were
2.8%, 10.4% and 6.2%, respectively.Statistical analysis
Statistical analysis was done using IBM SPSS Statistical
Package Version 20 (IBM SPSS Statistics for MAC, Ver-
sion 20.0. Armonk, NY: IBM Corp) and STATISTICA
5.0. (StatSoft, Tulsa, OK) for fitness/fat mass compari-
sons. The data were checked for completeness and de-
termined to be free of errors prior to statistical analysis.
Categorical variables including subject categorizations
into different aerobic fitness levels in overweight/obese
and lean children are reported based on the median split
in each group. Continuous variables are reported as
mean ± standard deviation (SD). For subgroup analysis,
the participants were divided based on their fitness levels
to lean-low fitness (L-LF), lean high-fitness (L-HF), over-
weight/obese low-fitness (OW-LF) and overweight /obese
high-fitness (OW-HF) groups.
To calculate study power based on the number of paired
participants, we used SP software (version 3.0.43) [31].
Based on previous evidence, and using a mean CCL2 of
222 pg/ml for obese children and 184 pg/ml for lean
children, we have power of 1.0 for detecting differences
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dren [22,31].
We tested cases and controls for differences between
the various variables, with comparisons between groups
were conducted using independent sample t-test. CCL2
and HOMA-IR were log transformed to ensure normali-
zation of data. Correlations were tested to explore the
relation of fitness and CCL2 levels using CCL2 and fit-
ness adjusted to lean body mass (VO2max-Lean) as the
dependent variables, and covariates including anthropo-
metric measures, body mass index (BMI), maturity off-
set, glucose, insulin, Homeostasis Model of Assessment-
Insulin Resistance (HOMA-IR), and lipid levels. Fitness
and CCL2 subgroup correlations were done using ana-
lysis of covariance (ANCOVA) with CCL2 as the de-
pendant variable and fitness level as the independent
variable, adjusting for chronological age, sex and matu-
rity offset. The criterion for statistical significance was
set at alpha = 0.05, adjusted for multiple analysis using
the Bonferroni method.
Results
The clinical, anthropometric and fitness measures are
detailed in Table 1. The groups were matched for sex,
chronological age, and maturity offset. The levels of fas-
ting glucose, fasting insulin, HOMA-IR, and fasting li-
pids were similar in the two groups as noted in Table 2.
To determine the effect of obesity in children on
CCL2 levels, the lean and obese CCL2 groups were com-
pared, and there was a statistically significant difference
in CCL2 levels between lean and obese children when
analyzed as a group (150.4 ± 61.85 pg/ml versus 112.7 ±
38 pg/ml) with a main effect for the OW-LF group
(F (3,32) = 3.2, p = 0.034) when compared to L-LF group
(Figure 1). In order to explore what factors contribute
to the differences between the two groups, we used
spearman’s correlation and multiple regression analyses
with CCL2 and variables including VO2max adjusted
to lean body mass (VO2max-Lean), sex, age, maturityTable 2 Metabolic parameters in study participants
Variable Lean Ove
Mean SD Mean
Insulin (μIU/ml) 17.50 18.30 14.60
FBG (mmol/l) 4.70 0.55 4.80
HOMA-IR 2.81 3.71 2.81
Cholesterol (mmol/l) 3.90 0.90 4.10
Triglycerides (mmol/l) 0.70 0.30 0.90
HDL (mmol/l) 0.99 0.24 0.88
LDL (mmol/l) 2.60 0.90 2.80
TC/HDL 4.10 1.40 4.80
FBG = fasting blood glucose; HOMA-IR = Homeostasis Model of Assessment-Insulin R
lipoprotein cholesterol; TC/HDL = total cholesterol/ high-density lipoprotein ratio; SDoffset, BMI, DEXA-measured fat mass percentage,
HOMA-IR, cholesterol, triglycerides, HDL, LDL, and
total cholesterol/HDL ratio. The result showed that
on Spearman’s correlation, BMI percentile and fat mass
correlated positively with CCL2 levels (Table 3), and mul-
tiple regression analysis showed that BMI is associated
with CCL2 levels (β12.43, SE 4.93, 95% CI (1.84, 23),
p =0.02).
To establish if CCL2 is a biomarker of fitness, we di-
vided the groups based on their fitness levels, and then
we compared CCL2 levels in L-LF, L-HF, OW-LF and
OW-HF groups. There was a main effect for group
(F (3,32) = 3.2, p = 0.036). Post-hoc analysis revealed that
the OW-LF group had higher level of CCL2 compared
to the L-LF group (p-value 0.034). When adjusted to
age, sex and maturity offset, the main effect for group
remained (F (3,29) = 3.1, p = 0.04). Post-hoc analysis re-
vealed that the OW-LF group had higher CCL2 levels
compared to both the L-LF (P-value 0.009) and the
L-HF group (p = 0.035). Importantly, OW-HF children had
CCL2 levels similar to L-LF and L-HF groups (Figure 1).
Discussion
In this study, we demonstrate that overweight and obese
children have higher circulating CCL2 levels when com-
pared to lean children.
OW-LF children have higher CCL2 concentrations
compared to L-LF and L-HF children adjusted for chro-
nological age, sex and maturity offset. Another impor-
tant observation is that OW-HF children have similar
CCL2 levels to lean children. Thus, fitness and fatness
modulate CCL2 levels in children.
Our results are in agreement with another recent
study that showed CCL2 levels were elevated in obese
compared to lean children, and in that study CCL2 le-
vels correlated with insulin resistance. CCL2 levels were
reduced when substantial weight loss was achieved, pro-
bably indicating an improvement of fitness, and its levels
increased in those who did not lose weight [22]. Therweight/Obese Difference (95% CI) P-value
SD
13.20 2.00 (−8.70, 12.70) 0.71
0.80 0.10 (−0.43, 0.64) 0.70
2.86 0.04 (−2.40, 2.40) 0.97
0.70 −0.25 (−0.81, 0.31) 0.38
0.40 −0.18 (−0.44, 0.07) 0.16
0.20 0.05 (−0.11, 0.21) 0.55
0.60 −0.21 (−0.72, 0.30) 0.41
1.20 −0.41 (−1.30, 0.51) 0.37
esistance; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density
= standard deviation. Independent sample t-test was used for analysis.
Figure 1 CCL2 in lean and overweight/obese children
according to aerobic fitness. Study participants (n = 36) were age,
sex and maturity offset matched to lean controls. Fasting blood
samples were analyzed for CCL2 (intra-assay CV = 6.2%). Aerobic
fitness was measured using a continuous cycling test to exhaustion,
with values expressed relative to fat-free mass. Group assignments
were based on median split of aerobic fitness values in overweight/
obese and lean children: overweight/obese, low fitness (OW-LF);
overweight/obese, high fitness (OW-HF); lean, low fitness (L-LF); lean,
high fitness (L-HF). A) Individual values of CCL2 B) Combined group
values. Significant correlations (P-value <0.05) are marked for
comparisons between obese children who have low fitness (OW-LF)
and lean children who have low (L-LF) and high (L-HF) fitness levels.
Table 3 Spearman’s correlation analysis of CCL2 and
variables including clinical, biochemical and metabolic
factors




BMI Percentile 0.414 0.010
LOG HOMA-IR −0.038 0.836







Correlation coefficients with P-values and 95% confidence intervals
are displayed.
Log HOMA-IR = logarithmic transformation of HOMA-IR;%FM DEXA = percentage
of fat mass on DEXA scans; VO2MAX Lean = VO2 MAX adjusted to lean mass;
TG = Triglycerides; HDL = high-density lipoprotein; LDL = low-density lipoprotein;
TC/HDL = total cholesterol to HDL ratio.
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and obese participants had similar insulin sensitivity,
while Roth et al. study participants had significant differ-
ences in their insulin levels and HOMA-IR based on
their BMI. This is a strength in our study, as it takes out
insulin resistance as a factor associated with obesity-
related inflammation, and isolates the effect of obesity
on CCL2 levels. In addition, lipid levels that may have
explained the differences in insulin sensitivity were not
reported in the study by Roth et al. Our lean and obese
participants had similar lipid levels, which may be the
result of less lipolysis with equivalent insulin sensitivity
in the obese group. In addition, the standardization of
fitness assessment using a formal exercise test, and thefact that participants were matched for age, sex and bio-
logical maturity is a unique component of our study.
Therefore, we propose that CCL2 serves a dual role as
a potential biomarker of fitness and inflammation in
obese children; CCL2 may aid the definition of fitness
levels and demarcate a group of children who have more
inflammation despite having similar metabolic profiles
to other obese children but may require more intensive
interventions to treat obesity-related inflammation.
A limitation of our study is the inability to determine
the source of CCL2; while the main source is probably
the adipocyte, fat mass did not differ between the OW-
LF and OW-HF groups. Possible explanations for this
observation are that the OW-LF group has larger and
more inflammatory adipocytes that produce more CCL2,
or that CCL2 is secreted by other tissues that were not
the subject of our investigation, like skeletal muscle,
liver, endothelium or monocytes. In obese adults, circu-
lating CCL2 and gene expression levels are higher in vis-
ceral compared to subcutaneous adipose tissue, and this
correlates directly with adipose tissue macrophage con-
tent and larger adipocytes. This process is not studied in
children in visceral fat but in subcutaneous adipose tis-
sue it appears to be less robust than in adults, although
macrophage content does correlate with adipocyte size
and both have an impact on the inflammatory response
in obesity [32]. Whether the OW-LF group has larger
adipocytes and more macrophage infiltration into the
adipose tissue that correlates with their higher CCL2
levels is unknown, but this group has a more robust
inflammatory response based on their CCL2 levels,
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their obesity.
While levels of CCL2 did not correlate with insulin
sensitivity in this study, it is known that CCL2 does
cause insulin resistance when mice are infused directly
with this chemokine, and there is some evidence that
this is also the case in adult humans although the evi-
dence is not conclusive [23,25,26]. It is quite important
to follow our patients to see if they develop insulin resist-
ance and how CCL2 levels correlate with this. It remains
to be seen if CCL2 can predict future metabolic outcomes
including obesity, dyslipidemia and dysglycemia.Conclusions
In summary, this is a report of a previously unknown as-
sociation of CCL2 as a potential biomarker of inflamma-
tion and fitness in overweight/obese children. Further
characterization of its role in obesity-related comorbi-
dities may open the door for more targeted interventions
including more focused exercise programs, nutraceutical
or pharmacological interventions that modulate CCL2
levels to tackle inflammation in obesity.
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